ArticleDrug design, development and therapy2026
Liposomal Bupivacaine Combined with Bupivacaine vs Ropivacaine for Paravertebral Blockade in Single-Port Video-Assisted Thoracoscopic Surgery: A Propensity-Matched Comparison of Postoperative Opioid Use.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the effect of preoperative single-injection paravertebral block using liposomal bupivacaine/bupivacaine mixture versus ropivacaine on cumulative postoperative opioid consumption in patients undergoing thoracic surgery. Methods: This retrospective cohort study included adult patients who underwent elective single-port video-assisted thoracoscopic surgery (wedge resection, segmentectomy, or lobectomy) between January 2024 and February 2026. Patients received an ultrasound-guided single-injection paravertebral block with either 0.5% ropivacaine (20 mL) or a mixture of 1.3% liposomal bupivacaine (10 mL) and 0.5% standard bupivacaine (10 mL). The primary outcome was cumulative postoperative opioid consumption throughout the hospitalization, delivered via patient-controlled analgesia (PCA) and converted to oral morphine milligram equivalents. Secondary outcomes included pain scores, time to first PCA request, postoperative adverse events, and length of stay. Propensity score matching (1:2) was performed to balance baseline clinical and intraoperative characteristics. Results: Among 492 eligible patients, 331 received ropivacaine and 161 received liposomal bupivacaine/bupivacaine combination. After matching, 210 and 108 patients were included in the ropivacaine and liposomal bupivacaine groups, respectively. The median cumulative postoperative opioid consumption was lower in the liposomal bupivacaine group (92.1 mg [IQR, 59.1-122.3]) than in the ropivacaine group (226.2 mg [IQR, 170.2-260.0]), with a median difference of 128.2 mg (95% CI, 111.0-143.9; Conclusion: For patients undergoing video-assisted thoracoscopic surgery, preoperative single-injection paravertebral blockade with liposomal bupivacaine/bupivacaine mixture was associated with lower cumulative postoperative opioid consumption and lower early postoperative pain scores than ropivacaine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.